Insights from 2023 ASH Annual Meeting


 

ASH 2023 Insights: "KarMMa-3 Trial - Ide-Cel vs. Standard Regimens in Patients With Triple-Class-Exposed R/R MM"

80 views
February 12, 2024
0 Comments
Login to view comments. Click here to Login
Myeloma